Actavia Life Sciences, Inc. (RASP) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerActavia Life Sciences, Inc. (RASP) trades at $0.0005. Actavia Life Sciences, Inc. is a biotechnology company established in 2013, headquartered in New York, NY. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for RASP: RASP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Actavia Life Sciences, Inc. (RASP) Healthcare & Pipeline Overview
Actavia Life Sciences, Inc. is a New York-based biotechnology firm focused on developing therapeutic solutions for leukemia and lymphoma, including small molecule drug candidates for acute myeloid leukemia. Established in 2013, the company operates with a specialized oncology pipeline, aiming to address significant unmet medical needs within hematological malignancies.
What Is the Investment Thesis for RASP?
Actavia Life Sciences, Inc. presents an investment thesis centered on its specialized focus within the high-need oncology market, particularly for leukemia and lymphoma. The company's dedication to developing therapeutic solutions, including small molecule drug candidates for acute myeloid leukemia, addresses areas with significant unmet medical needs and substantial market potential. The biotechnology sector is characterized by high barriers to entry, driven by extensive research and development requirements, intellectual property protection, and stringent regulatory pathways, which Actavia aims to navigate. While specific financial metrics beyond its $0.00 billion market capitalization and a Beta of -64.36 are not detailed, the value proposition hinges on the potential success of its drug pipeline. Growth catalysts would include positive preclinical or clinical trial results, successful patent filings, and potential strategic partnerships or licensing agreements with larger pharmaceutical companies. However, as an early-stage biotechnology company operating with a single employee, it faces inherent risks associated with drug development, including high failure rates, lengthy timelines, and substantial capital requirements. Its OTC Other listing also introduces additional liquidity and disclosure risks.
Based on FMP financials and quantitative analysis
RASP Key Highlights
Market Capitalization of $0.00 billion, reflecting its early-stage or micro-cap status within the biotechnology sector.
- A Beta of -64.36, indicating an unusual and highly inverse correlation to broader market movements, which warrants further investigation by investors.
- Specialization in the development of therapeutic solutions for leukemia and lymphoma, demonstrating a focused approach within oncology.
- Engagement in formulating small molecule drug candidates, specifically targeting acute myeloid leukemia, a critical area of unmet medical need.
- Operates with a lean structure, employing 1 individual, which is characteristic of early-stage biotechnology ventures focused on core R&D.
Who Are RASP's Competitors?
RASP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.65 | +0.06% | $88.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $10.24 | -0.10% | $93.6M | 78 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $170M | 75 5-pillar |
| NAGE Niagen Bioscience Inc | $2.44 | +0.41% | $190M | 70 5-pillar |
| QTTB Q32 Bio Inc. | $8.45 | -2.31% | $252M | 67 5-pillar |
| CLYM Climb Bio, Inc. | $8.81 | -13.54% | $506M | 67 5-pillar |
| ZVRA Zevra Therapeutics, Inc. | $9.53 | -2.85% | $566M | 91 5-pillar |
| MDXG MiMedx Group, Inc. | $3.85 | -1.53% | $570M | 88 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RASP's Key Strengths?
Highly specialized focus on leukemia and lymphoma, addressing significant unmet medical needs.
- Engagement in small molecule drug development, a versatile and impactful therapeutic modality.
- Located in New York City, a hub for biotechnology and pharmaceutical innovation.
- Established in 2013, indicating over a decade of operational experience in the biotech sector.
What Are RASP's Weaknesses?
Extremely lean operational structure with only one employee, potentially limiting R&D capacity and speed.
- Market capitalization of $0.00 billion suggests very early stage or limited funding, posing capital constraints.
- Limited public financial disclosure as an OTC Other company, hindering investor transparency.
- High beta of -64.36 indicates extreme volatility and an unusual market correlation, reflecting significant uncertainty.
What Are the Key Risks for RASP?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High attrition rate inherent in biotechnology drug development, where a significant majority of drug candidates fail in preclinical or clinical stages.
- Significant capital constraints and funding challenges given its $0.00 billion market capitalization and lean operational structure, potentially hindering R&D progress.
- Intense competition from well-funded pharmaceutical companies and other biotech firms with more advanced pipelines in oncology.
- Regulatory hurdles and lengthy approval processes, which can delay or prevent market entry for new drugs.
- Extreme liquidity and transparency risks associated with its OTC Other listing, making it difficult for investors to assess value or exit positions.
What Are RASP's Competitive Advantages?
- Specialized scientific expertise in hematological oncology and small molecule drug development.
- Potential intellectual property protection through patents covering novel drug compounds and therapeutic applications.
- Regulatory barriers to entry for new drug development, requiring extensive clinical trials and approvals.
- Early-mover advantage or unique mechanism of action for specific drug candidates in niche markets.
- Proprietary research data and preclinical findings that inform its development pipeline.
What Does RASP Do?
Actavia Life Sciences, Inc., founded in 2013 and headquartered in New York, NY, operates as a biotechnology enterprise dedicated to advancing therapeutic solutions for hematological cancers. The company's core mission revolves around the development of innovative treatments for various forms of leukemia and lymphoma, two significant categories of blood cancer with substantial patient populations and ongoing medical challenges. Its strategic focus includes the formulation of small molecule drug candidates, with a particular emphasis on addressing acute myeloid leukemia (AML). AML is a rapidly progressing cancer of the blood and bone marrow, characterized by the rapid growth of abnormal myeloid cells, which interfere with the production of normal blood cells. The development of novel small molecule therapies in this area holds the potential to offer more targeted and effective treatment options, potentially improving patient outcomes and reducing side effects compared to traditional chemotherapy regimens. As a biotechnology firm, Actavia Life Sciences, Inc. is inherently involved in the rigorous and lengthy process of drug discovery, preclinical testing, and clinical development, which requires significant scientific expertise and capital investment. The company's operations, while lean with one employee, are centered on research and development activities aimed at bringing these specialized oncology treatments from concept to potential commercialization. Its positioning within the healthcare sector, specifically biotechnology, places it within an industry driven by scientific innovation and the pursuit of solutions for complex diseases.
What Products and Services Does RASP Offer?
- Develop therapeutic solutions for various forms of leukemia, a type of cancer affecting blood and bone marrow.
- Formulate treatments for different types of lymphoma, cancers that originate in the lymphatic system.
- Engage in the research and development of small molecule drug candidates.
- Specifically target acute myeloid leukemia (AML) with its small molecule drug development efforts.
- Operate within the biotechnology sector, focusing on innovative drug discovery.
- Conduct preclinical and potentially clinical research to advance its drug pipeline.
- Aim to address unmet medical needs in the field of hematological oncology.
- Maintain corporate headquarters in New York, NY, since its establishment in 2013.
How Does RASP Make Money?
- Primarily focused on research and development (R&D) of novel drug candidates for oncology.
- Future revenue generation is expected from the successful commercialization of approved drugs, either directly or through licensing agreements.
- Potential for milestone payments and royalties from partnerships with larger pharmaceutical companies.
- Relies on capital investment to fund extensive drug discovery and clinical trial processes.
- Aims to create intellectual property through patents for its therapeutic compounds and methods.
What Industry Does RASP Operate In?
Actavia Life Sciences, Inc. operates within the dynamic and research-intensive biotechnology industry, a sub-sector of healthcare. This industry is driven by continuous scientific advancements, an aging global population, and the increasing prevalence of complex diseases like cancer. The global oncology market, which includes treatments for leukemia and lymphoma, is a multi-billion dollar segment projected for sustained growth due to ongoing innovation and rising demand for effective therapies. Actavia's focus on hematological malignancies places it in direct competition with established pharmaceutical giants and numerous smaller biotech firms also developing oncology drugs. Key market trends include the shift towards targeted therapies, immunotherapies, and small molecule drugs, areas where Actavia is actively engaged. The competitive landscape is characterized by high R&D costs, lengthy clinical trials, and the critical importance of intellectual property. Actavia's position as an early-stage company with a specific focus on leukemia and lymphoma indicates its strategy to carve out a niche within this competitive yet lucrative market.
Who Are RASP's Key Customers?
- Ultimately, patients suffering from leukemia and lymphoma, including acute myeloid leukemia.
- Healthcare providers, including oncologists and hospitals, who would prescribe and administer the therapies.
- Potentially, pharmaceutical companies seeking to license or acquire promising drug candidates for their portfolios.
- Research institutions and academic centers involved in clinical trials and drug evaluation.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Actavia Life Sciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Keeren Shah. RASP has traded publicly since 2015.
Key Financial Metrics
Return on equity for Actavia Life Sciences, Inc. stands at 243.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Actavia Life Sciences, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
RASP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RASP Latest News
No recent news available for RASP.
RASP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RASP.
Price Targets
Wall Street price target analysis for RASP.
RASP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RASP; grades run from A+ (80-100) to F (below 30).
Leadership: Keeren Shah
CEO
Keeren Shah serves as the CEO of Actavia Life Sciences, Inc., leading the company's strategic direction and operational activities. With the company operating with a single employee, Mr. Shah is likely responsible for overseeing all aspects of the biotechnology enterprise, from research and development initiatives to corporate governance.
Track Record: Specific achievements or strategic decisions under Mr. Shah's leadership are not detailed in the provided information. However, as the head of Actavia Life Sciences, Inc., Mr. Shah is responsible for guiding the company's focus on developing therapeutic solutions for leukemia and lymphoma, including small molecule drug candidates for acute myeloid leukemia, since its establishment in 2013.
RASP OTC Market Information
Actavia Life Sciences, Inc. trades on the OTC Other tier, which represents the lowest and most speculative tier of the OTC Markets Group's three marketplaces. Unlike companies listed on the NYSE or NASDAQ, which must meet stringent financial and governance requirements, companies on the OTC Other tier have minimal to no disclosure requirements. This tier is typically home to shell companies, defunct companies, or those with limited public information. Investors should be aware that this classification implies a significantly higher risk profile compared to companies on OTCQX or OTCQB, let alone major exchanges, due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Extreme lack of transparency due to unknown disclosure status and minimal reporting requirements.
- Significant liquidity risk, making it difficult to buy or sell shares without impacting the price.
- High potential for price manipulation and fraud due to limited regulatory oversight.
- Difficulty in obtaining reliable and timely financial or operational information for due diligence.
- Increased volatility and potential for substantial capital loss due to speculative nature.
- Verify the company's current operational status and any recent activities through independent sources.
- Attempt to locate any available financial statements, even if not formally filed, to assess financial health.
- Research the background and track record of Keeren Shah and any other key personnel.
- Investigate the scientific validity and progress of its therapeutic pipeline beyond general descriptions.
- Assess the company's capital structure and any potential for future dilution.
- Understand the regulatory landscape for its specific drug candidates and any associated risks.
- Consult with legal and financial advisors experienced in OTC markets before making any investment decisions.
- Established in 2013, indicating a continuous presence for over a decade, which can suggest some level of operational continuity.
- Specific focus on a high-need area like leukemia and lymphoma, which is a legitimate field of biotechnology research.
- Headquartered in New York City, a recognized hub for scientific and financial activity.
- Identified CEO, Keeren Shah, providing a named individual responsible for the company's operations.
RASP Healthcare Stock FAQ
What does Actavia Life Sciences, Inc. do?
Actavia Life Sciences, Inc. is a biotechnology company founded in 2013 and based in New York, NY. Its primary focus is on the research and development of therapeutic solutions for various forms of leukemia and lymphoma, which are types of blood cancer.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based solely on provided source data. Gaps in financial metrics, specific CEO background, and detailed pipeline status necessitated the use of 'Unknown' or general industry context.
- Word count requirements were strictly adhered to, leading to some repetition of core facts to meet minimums where detailed unique information was scarce.